ストックスクリーナーアプリを入手
3.56
5.01%
0.17
プレマーケット:
3.48
-0.08
-2.25%
Senti Biosciences Inc (SNTI) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amerant Bancorp Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - GlobeNewswire Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc - ACCESS Newswire
Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise - insights.citeline.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc.GMED - PR Newswire
Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc - ACCESS Newswire
Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - The Manila Times
Senti Bio CEO Reveals Next-Gen Gene Circuit Platform: Live Webull Biotech Investment Presentation Coming May 29 - Stock Titan
Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Develo - GuruFocus
Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Development | SNTI Stock News - GuruFocus
Senti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell Therapy - Nasdaq
Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 - Yahoo Finance
Senti Bio Cancer Therapy Achieves 71% Response Rate in AML Patients, Secures Additional $1M CIRM Grant - Stock Titan
SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com
Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire
Senti Biosciences advances AML treatment with SENTI-202 trial By Investing.com - Investing.com Nigeria
Senti Biosciences advances AML treatment with SENTI-202 trial - Investing.com
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 - The Manila Times
Renaissance Technologies LLC Makes New $181,000 Investment in Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World
Senti Biosciences Reports Positive Phase 1 Results for SENTI-202 in Acute Myeloid Leukemia Treatment - Nasdaq
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI - FinancialContent
Senti Biosciences’ (SNTI) Buy Rating Reiterated at Chardan Capital - Defense World
Senti Biosciences (SNTI) Maintains Buy Rating with Target Price Unchanged | SNTI Stock News - GuruFocus
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
SNTI: Senti Bio Shares Positive Phase 1 Trial Results for SENTI-202 | SNTI Stock News - GuruFocus
Senti Bio Releases Virtual Investor "What This Means” Segment - The Manila Times
Senti Biosciences Announces Positive Data for SENTI-202 in Phase 1 Trial at AACR Annual Meeting 2025 - Nasdaq
Senti Bio Releases Virtual Investor “What This Means” Segment - TradingView
Senti Biosciences, Inc. Being Investigated on Behalf of Senti Biosciences, Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
Senti Bio to Present at the Citizens JMP Life Sciences Conference - The Manila Times
Breakthrough: Senti Bio's SENTI-202 Shows Promise in Treating Resistant Blood Cancer - Stock Titan
Market Momentum Report: Prairie Operating Co (PROP)’s Positive Close at 4.10 - DWinneX
Closing Figures Unveiled: Senti Biosciences Inc (SNTI) Drop -27.20, Closes at 3.64 - DWinneX
An Analysis of Senti Biosciences Inc (SNTI)’s Potential Price Growth - knoxdaily.com
Senti Biosciences to Showcase New Cell & Gene Therapy Data at AACR Annual Meeting 2025 - geneonline.com
Senti Biosciences reports promising SENTI-202 trial results - Investing.com
SNTI’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Senti Biosciences Pauses Enrollment in Hepatocellular Carcinoma Trial in China; Shares Fall - marketscreener.com
SNTI’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Senti Biosciences, Inc. Reports Additional Positive Preliminary Data from A Phase 1 Clinical Trial of SENTI-202 - marketscreener.com
Senti Bio's SENTI-202, A First-In-Class Off-The-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results In The Treatment Of Patients With Relapsed/Refractory AML - marketscreener.com
Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML - The Manila Times
0.86%
1.24%
大文字化:
|
ボリューム (24 時間):